Market OverviewThe Global Breast Cancer Therapeutics Market  remains one of the most prevalent forms of cancer worldwide, ...

Ado-trastuzumab emtansine led to improved overall survival and invasive disease–free survival over trastuzumab in patients ...

After a phase 3 study showed a promising pCR rate with HLX11, the pertuzumab biosimilar’s BLA has been accepted for review by the FDA.

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Shanghai Henlius Biotech, Inc. (“Henlius”) announced FDA acceptance of the Biologics License Application (BLA) for ...

Healthcare organisations, including the Kenyan Network of Cancer Organisations (KENCO) and the NCD Alliance Kenya (NCDAK), have condemned the deteriorating health services for cancer patients, calling ...

T-DM1 was tolerable in HER2-positive biliary tract adenocarcinoma but did not significantly improve progression-free survival ...

The patients were randomly assigned to receive adjuvant treatment with T-DM1 at 3.6 mg/kg (n=743) or trastuzumab at 6 mg/kg (n=743) every 3 weeks for 14 cycles. Baseline characteristics were ...

Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs ...

after a first course of chemotherapy and dual blockade and HER2 blockade with pertuzumab [Perjeta]/trastuzumab [Herceptin], usually treat with the maintenance treatment with pertuzumab/trastuzumab ...

Estimated overall survival (OS) at 7 years was 89.1% with adjuvant T-DM1 versus 84.4% with adjuvant trastuzumab (Herceptin). Consistent with earlier reports from the study, the 7-year invasive ...